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CASE REPORT
Rare MLL-ELL fusion transcripts 
in childhood acute myeloid leukemia—
association with young age and myeloid 
sarcomas?
Ioannis Panagopoulos1,2*, Ludmila Gorunova1,2, Gitte Kerndrup3, Signe Spetalen4, Anne Tierens5, 
Liv T. N. Osnes6, Kristin Andersen1,2, Lil‑Sofie Ording Müller7, Marit Hellebostad8, Bernward Zeller9 
and Sverre Heim1,2,10
Abstract 
Background: The chromosomal translocation t(11;19)(q23;p13) with a breakpoint within subband 19p13.1 is found 
mainly in acute myeloid leukemia (AML) and results in the MLL‑ELL fusion gene. Variations in the structure of MLL‑ELL 
seem to influence the leukemogenic potency of the fusion in vivo and may lie behind differences in clinical features. 
The number of cases reported so far is very limited and the addition of more information about MLL‑ELL variants is 
essential if the possible clinical significance of rare fusions is to be determined.
Case presentation: Cytogenetic and molecular genetic analyses were done on the bone marrow cells of a 
20‑month‑old boy with an unusual form of myelomonocytic AML with multiple myeloid sarcomas infiltrating bone 
and soft tissues. The G‑banding analysis together with FISH yielded the karyotype 47,XY, +6,t(8;19;11)(q24;p13;q23). 
FISH analysis also demonstrated that MLL was split. RNA‑sequencing showed that the translocation had generated 
an MLL‑ELL chimera in which exon 9 of MLL (nt 4241 in sequence with accession number NM_005933.3) was fused to 
exon 6 of ELL (nt 817 in sequence with accession number NM_006532.3). RT‑PCR together with Sanger sequencing 
verified the presence of the above‑mentioned fusion transcript.
Conclusions: Based on our findings and information on a few previously reported patients, we speculate that young 
age, myelomonoblastic AML, and the presence of extramedullary disease may be typical of children with rare MLL‑ELL 
fusion transcripts.
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Background
The chromosomal translocation t(11;19)(q23;p13) has 
been reported in both acute myeloid (AML) and acute 
lymphoblastic leukemia (ALL) [1]. Breakpoints within 
subband 19p13.3 are found in both ALL (primarily in 
infants and children) and AML with the translocation 
t(11;19)(q23;p13.3) leading to the fusion of MLL with 
MLLT1 (also known as ENL, LTG19, and YEATS1) gener-
ating an MLL-MLLT1 fusion gene [2]. Breakpoints within 
subband 19p13.1 are found mostly in AML where the 
translocation t(11;19)(q23;p13.1) results in the MLL-ELL 
fusion gene [3]. MLL-ELL fusions were recently found 
also in two biphenotypic leukemias [4]. Two other MLL-
fusion genes have also been reported in t(11;19)-positive 
AML. A recurrent MLL-MYO1F [translocation t(11;19)
(q23;p13.2)] fusion gene was seen in infant AML [5, 6], 
whereas an MLL-SH3GL1 fusion [translocation t(11;19)
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(q23;p13.3)] was reported in a case of childhood AML 
[7].
In the majority of MLL-ELL fusion transcripts, exon 9, 
10, 11 or 12 of MLL is fused to exon 2 of ELL [3, 8–13]. 
A variant form of MLL-ELL fusion transcript has been 
reported in chronic myelomonocytic leukemia in which 
MLL exon 9 (exon 10 according to Nilson et  al. [14]) 
was fused to ELL exon 3 [15]. Furthermore, in a case of 
congenital acute monoblastic leukemia with a three-way 
translocation t(1;19;11)(p36;p13.1;q23), De Braekeler 
et al. showed that the genomic breakpoints in MLL and 
ELL occurred in introns 9 and 5, respectively [8, 16].
The leukemogenic potency of MLL-ELL fusion genes 
was demonstrated in murine model systems [17]. More-
over, variant forms of MLL-ELL were shown to impair 
transforming activities in  vitro [12]. These observations 
suggest that variations in MLL-ELL structure may influ-
ence leukemogenic potency of the fusion also in  vivo, 
and they hint that such variability may be behind varia-
tion in clinical features. Because so few such cases have 
been reported, the addition of more cases with MLL-ELL 
variants is essential if the possible clinical significance of 
rarer fusions is to be determined. In the present study, we 
report a childhood leukemia in which a three-way trans-
location caused the fusion of exon 9 of MLL with exon 6 
of ELL. To the best of our knowledge, this is only the sec-
ond case in which exon 6 of ELL was found to be fused to 
MLL [8, 16, 18].
Case presentation
Ethics statement
The study was approved by the regional ethics committee 
(Regional komité for medisinsk forskningsetikk Sør-Øst, 
Norge, http://helseforskning.etikkom.no), and written 
informed consent was obtained from the patient’s parents 
to publication of the case details. The ethics committee’s 
approval included a review of the consent procedure. All 
patient information has been anonymized.
Clinical presentation
A 20-month-old, previously healthy boy presented with 
intermittent pain in the hip. The boy’s general condi-
tion was reduced, he was pale and weak, and passive 
movements in the right hip were painful. His spleen was 
slightly enlarged, whereas liver size was normal. Blood 
tests revealed anemia (hemoglobin 8.2  g/dL), thrombo-
cytopenia (64  ×  109/L), normal white blood cell count 
(11.9  ×  109/L) with monocytosis (1.5  ×  109/L), and 
immature myeloid cells were seen in the blood smear 
(Fig. 1).
A bone marrow investigation (which was repeated 
several times due to diagnostic difficulties) and a biopsy 
from one of the bony lesions revealed morphologically a 
myeloid hyperplasia comprised of predominantly mono-
morphonuclear cells. Erythropoiesis and megakaryopoie-
sis were sparse without dysplasia and decreased further 
with time until they were nearly absent in the later biop-
sies. The monomorphonuclear cells were positive for 
CD4 and CD56. The proportion of CD34+ and CD117+ 
cells was not increased. Further, flow cytometry analysis 
(Fig.  2) confirmed the normal distribution of CD34+ or 
CD117+ precursor cells but revealed two distinct myeloid 
populations comprised of 68  % CD15 bright +/HLA-DR− 
granulocytic cells and 15  % CD64 bright +/HLA-DR− 
monocytic cells. Both lineages showed marker expression 
consistent with a shift to early stages as well as abnor-
mal expression of CD56. In addition, CD13, a common 
myeloid marker, was not expressed in the early stages 
of these myeloid populations whereas abnormal expres-
sion of CD4 was demonstrated on early granulocytes. 
Only 50  % of the granulocytes had acquired expression 
of CD11b and to a lesser extent CD16 which is consist-
ent with maturation beyond the promyelocyte stage. 
However, CD10+/CD16+ end-stage neutrophils were not 
identified. Around 20 % of the monocytes were negative 
for CD35 and CD14 which are features of promonocytes. 
Based on the above immunophenotypic findings alone, a 
definitive diagnosis of acute myeloid leukemia could not 
be made.
Whole body magnetic resonance imaging (WBMRI) 
showed marked spiculated periosteal reaction and new 
Fig. 1 Microscopic picture of peripheral blood smear of the AML 
patient from the time of admission to the local pediatric department 
showing a a myeloblast (arrow) and a lymphocyte. b A promyelocyte 
(arrow) and a vacuolated monocyte. Magnification 100×
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bone formation in the mandible, iliac bones, and bilater-
ally in the distal femur (Fig. 3a–d). In addition, there were 
widespread bone lesions with infarctions and necroses 
involving the skull base, mandible, scapulae, pelvic 
bones, femurs, and tibia. There was soft tissue involve-
ment of the lower extremities with edema in the muscles 
and subcutaneous tissue and fluid along the facial planes 
(Fig. 3a–d).
The G-banding analysis of bone marrow metaphase 
cells at diagnosis showed 11 cells carrying an extra 
chromosome 6 as well as the chromosomal transloca-
tion t(11;19)(q23;p13) yielding the karyotype 47,XY, 
+6,t(11;19)(q23;p13) [11] (Fig. 4a).
Interphase FISH analyses of bone marrow cells using 
the Cytocell multiprobe ALL panel (Cytocell, http://www.
cytocell.co.uk/) showed a split signal of the MLL locus in 
146 out of 201 investigated interphase nuclei (data not 
shown). FISH analysis of metaphase spreads using the 
MLL breakpoint probe (Cytocell, http://www.cytocell.
co.uk/) showed that the red signal (distal) had moved not 
to chromosome 19 but to the q arm of chromosome 8 
(Fig.  4b). Thus, the modified karyotype after G-banding 
analysis and FISH was 47,XY, +6,t(8;19;11)(q24;p13;q23) 
[11] (Fig. 4a, b).
Mainly on the basis of the detected MLL-rearrange-
ment, we interpreted the boy’s disease as an unusual 
form of myelomonocytic AML with multiple myeloid 
sarcomas infiltrating bone and soft tissues.
During the investigation, the patient’s extensive skel-
etal lesions increased causing therapy-resistant pain and 
Fig. 2 Bivariate dot plots of the flow cytometric analysis of the bone marrow aspirate. The color codes for the different cell subsets are as follows: 
green for granulocytes, blue for monocytes, purple for CD34 positive precursors, yellow for lymphocytes, and dark blue for erythroid precursors. Dot 
plot a and b show normal light scatter signals and normal expression of CD45 of all cell populations. No increase of CD34/CD117 positive cells was 
demonstrated as can be seen in dot plot c. Dot plot d shows partial loss of CD13 expression on monocytes as well as on granulocytes and shift to 
immaturity of the granulocytes of which the majority were negative for CD11b. The aberrant expression of CD56 by granulocytes and monocytes is 
demonstrated in dot plot e. Immature granulocytes were positive for CD4 as shown in dot plot f
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his general condition deteriorated. After 3 weeks, AML-
directed therapy was begun according to the NOPHO-
DBH AML 2012 protocol [19]. He received five courses 
(MEC, ADxE, HAM, HA3E, FLA) at 5–6 weeks intervals. 
For details, see Additional file 1: Figure: S1.
Clinically, the boy recovered rather quickly. Evaluation 
before course two showed no remaining MLL-rearranged 
cells by FISH in the bone marrow. MRI controls of his 
bony lesions demonstrated continuous, but slow, regres-
sion. At 9 months after cessation of treatment, the boy is 
Fig. 3 Coronal water‑sensitive, fat‑suppressed MRI‑sequences of the mandible (a), whole‑body (b), pelvis, and femurs of the AML patient (c, d) 
showing extensive infarcts in several bones (arrows). In the mandible and iliac wings, there was marked, spiculated cortical reaction and new bone 
formation (arrowheads) with destruction of the underlying skeleton (asterisk). Subtracted post contrast T1 fat suppressed images of the pelvis and 
femurs showed low‑signal avascular areas with a peripheral rim of enhancement caused by the multiple infarcts (arrows). There was soft tissue 
edema in the lower extremities. The kidneys were slightly enlarged
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Fig. 4 Cytogenetic, FISH, and PCR analyses of the AML patient. a G‑banded karyotype showing trisomy 6, der(8), der(11), and der(19) of the 
t(8;19;11)(q24;p13;q23) together with the corresponding normal chromosome homologs; breakpoint positions are indicated by arrows. b FISH 
using an MLL breakapart probe showed rearrangement of MLL. The 3´‑end part of the MLL gene (red probe) has moved to the q arm of the der(8), 
while the 5´‑end part of the gene (green probe) remains on 11q23 of the der(11). c The initial RT‑PCR amplifications for the detection of a possible 
MLL‑ELL fusion transcript. Lane 1, nested PCR with the forward primers located in exon 7 of MLL and reverse primers located in exon 4 of ELL (MLL‑
3947F1/ELL‑415R) failed to amplify any cDNA fragments. Lane 2, amplification of a cDNA fragment of the ABL1 gene using the primers ABL1‑91F1 
and AsBL1‑404R1 suggested that the synthesized cDNA was of good quality. d RT‑PCR using a new reverse primer located in exon 8 of ELL (primer 
ELL‑1044R1) and a forward primer located in exon 7 of MLL (primer MLL‑3878F) amplified a cDNA fragment. M, 1 Kb DNA ladder. e Partial sequence 
chromatogram of the amplified fragment using the primers MLL‑3878F and ELL‑1044R1 showing the junction of the MLL‑ELL chimeric transcript
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clinically healthy. As expected, MRI still shows several 
small residual bone lesions undergoing regression. Unex-
pectedly, however, the patient has developed a new, small 
(about 5 %) clone in the bone marrow with a solitary 7q 
deletion. This may or may not represent an emerging sec-
ondary malignancy [20–23], and the situation is being 
monitored closely to see whether the clone expands and 
gives rise to hematologically recognizable disease.
Initial RT‑PCR experiments
Total RNA, isolated from the patient’s bone marrow 
at the time of diagnosis, was reverse-transcribed using 
iScript Advanced cDNA Synthesis Kit for RT-qPCR (Bio-
Rad Laboratories, Oslo, Norway) and cDNA correspond-
ing to 20  ng total RNA was used as template in PCR 
amplifications as previously described [24, 25]. The initial 
RT-PCR with the primer set MLL-3878F/ELL-498R1 as 
well as nested PCR with the primers MLL-3947F1/ELL-
415R (the sequences of the primers are listed in Table 1) 
failed to amplify any cDNA fragments (Fig.  4c). At the 
same time, use of the primer set ABL1-91F/ABL1-404R1 
led to amplification of an ABL1 cDNA fragment sug-
gesting that the synthesized cDNA was of good quality 
(Fig. 4c).
RNA‑sequencing
Because of the negative RT-PCR results, the less than 
typical cytogenetic findings, and the clinical picture, 
three µg of the total RNA extracted from the patients’ 
bone marrow at the time of diagnosis were subjected 
to high-throughput paired-end RNA-sequencing at the 
Norwegian Sequencing Centre, Oslo University Hospital 
(http://www.sequencing.uio.no/) as described elsewhere 
[24, 26]. The raw sequencing data were subsequently ana-
lyzed using FusionCatcher which is a program designed 
to detect fusion genes from high throughput sequenc-
ing data [27]. More than 100 potential fusion transcripts 
were found (Additional file 2: Table: S1), among them an 
MLL-ELL in which exon 9 of MLL (nt 4241 in sequence 
with accession number NM_005933.3) was fused to 
exon 6 of ELL (nt 817 in sequence with accession num-
ber NM_006532.3). No reciprocal ELL-MLL fusion tran-
script was found.
In order to verify the fusion obtained with Fusion-
Catcher, we used the “grep” command utility [28] to 
search for expressions composed of 10 nt of MLL and 10 
nt of ELL upstream and downstream of the fusion point, 
respectively (Table  2). Using the expression “GACTT 
TAAGGTGGCCAACAT” which is composed of 10 
nt, “GACTTTAAGG”, from MLL and 10 nt, “TGGC 
CAACAT”, from ELL, 38 sequences were retrieved 
(Table 2).
Molecular genetic confirmation of the fusion
PCR with the MLL-3878F and ELL-1044R1 primer com-
bination (Table 1) amplified a fragment from the patient’s 
bone marrow cDNA (Fig. 4d). Sanger sequencing of the 
amplified product showed that it was a chimeric MLL-
ELL cDNA fragment in which exon 9 of MLL was fused 
to exon 6 of ELL, i.e., the same MLL-ELL fusion tran-
script found by RNA-sequencing (Fig. 4e; Table 2).
Conclusions
We report a case of AML genetically characterized by a 
three-way translocation, t(8;19;11)(q24;p13;q23), leading 
to rearrangement of the MLL gene and the generation of 
a chimeric MLL-ELL transcript with fusion of MLL exon 
9 to ELL exon 6. The initial RT-PCR amplifications relied 
on forward primers located in exon 7 of MLL and reverse 
primers located in exon 4 of ELL; this choice was based 
on findings in previous studies in which MLL was shown 
to fuse with exon 2 or 3 of ELL [3, 10, 11, 15, 29, 30]. The 
PCRs with these primer sets (first PCR with MLL-3878F/
ELL-498R1, then nested PCR with the primers MLL-
3947F1/ELL-415R) failed to amplify any cDNA frag-
ments. It was a combination of three methods—banding 
Table 1 Primers used for PCR amplification and Sanger sequencing analyses
Name Sequence (5´– >3´) Direction Position/exon Reference sequence Gene
MLL‑3735F CCCATCAGCAAGAGAGGATCCTGC Forward 3758‑3781/7 NM_005933.3 MLL (KMT2A)
MLL‑3878F AGTCAAGCAAGCAGGTCTCCCAGC Forward 3901‑3924/7 NM_005933.3 MLL (KMT2A)
MLL‑3947F1 GCCACCTACTACAGGACCGCCAAG Forward 3947‑3970/7 NM_005933.3 MLL (KMT2A)
ELL‑415R1 GGCACACACCGTGATCTTGTCCTG Reverse 438‑415/4 NM_006532.3 ELL
ELL‑498R1 TTGATGACAATGGCACTTCGGCTC Reverse 498‑521/4 NM_006532.3 ELL
ELL‑960R1 TCCAAGGAGGCTGCCAGTGCTC Reverse 981‑960/7 NM_006532.3 ELL
ELL‑1044R1 CGATGAAATCAGGAGGCTGCAGC Reverse 1066‑1044/8 NM_006532.3 ELL
ABL1‑91F1 CAGCGGCCAGTAGCATCTGACTTTG Forward 280‑304/2 NM_005157.5 ABL1
ABL1‑404R1 CTCAGCAGATACTCAGCGGCATTGC Reverse 617‑593/3 NM_005157.5 ABL1
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Table 2 Sequences retrieved with the «grep» command using the expression “GACTTTAAGGTGGCCAACAT”
ATGGAGTCCACAGGATCAGAGTGGACTTTAAGGTGGCCAACATGAGTGCTAAGGACGGCACGTGTACACTGCAGGACTGCATGTACAAGGATGTGCAGAAGGACTG‑
GCCTGGCTACTCGGAGGGGG
GTTCTAAGCAAAAAATTCCAGCAGATGGAGTCCACAGGATCAGAGTGGACTTTAAGGTGGCCAACATGAGTGCTAAGGACGGCACGTGTACACTGCAGGACTGCAT‑
GTACAAGGATGTGCAGAAGG
AAAAAATTCCAGCAGATGGAGTCCACAGGATCAGAGTGGACTTTAAGGTGGCCAACATGAGTGCTAAGGACGGCACGTGTACACTGCAGGACTGCATGTA-
CAAGGATGTGCAGAAGGACTGGCCTG
CCTCAGCACTCTCTCCAATGGCAATAGTTCTAAGCAAAAAATTCCAGCAGATGGAGTCCACAGGATCAGAGTGGACTTTAAGGTGGCCAACATGAGTGCTAA-
GGACGGCACGTGTACACTGCAGGA
GCACTCTCTCCAATGGCAATAGTTCTAAGCAAAAAATTCCAGCAGATGGAGTCCACAGGATCAGAGTGGACTTTAAGGTGGCCAACATGAGTGCTAAGGACG-
GCACGTGTACACTGCAGGACTGCA
AATGCAGGCACTTTGAACATCCTCAGCACTCTCTCCAATGGCAATAGTTCTAAGCAAAAAATTCCAGCAGATGGAGTCCACAGGATCAGAGTGGACTTTAAGGTGGC-
CAACATGAGTGCTAAGGAC
GTGGACTTTAAGGTGGCCAACATGAGTGCTAAGGACGGCACGTGTACACTGCAGGACTGCATGTACAAGGATGTGCAGAAGGACTGGCCTGGC-
TACTCGGAGGGGGACCAGCAGCTGCTGAAGCGG
CCTCAGCACTCTCTCCAATGGCAATAGTTCTAAGCAAAAAATTCCAGCAGATGGAGTCCACAGGATCAGAGTGGACTTTAAGGTGGCCAACATGAGTGCTAA-
GGACGGCACGTGTACACTGCAGGA
CCTCAGCACTCTCTCCAATGGCAATAGTTCTAAGCAAAAAATTCCAGCAGATGGAGTCCACAGGATCAGAGTGGACTTTAAGGTGGCCAACATGAGTGCTAA-
GGACGGCACGTGTACACTGCAGGA
CTCTCTCCAATGGCAATAGTTCTAAGCAAAAAATTCCAGCAGATGGAGTCCACAGGATCAGAGTGGACTTTAAGGTGGCCAACATGAGTGCTAAGGACG-
GCACGTGTACACTGCAGGACTGCATGT
CTCTCTCCAATGGCAATAGTTCTAAGCAAAAAATTCCAGCAGATGGAGTCCACAGGATCAGAGTGGACTTTAAGGTGGCCAACATGAGTGCTAAGGACG-
GCACGTGTACACTGCAGGACTGCATGT
GAACATCCTCAGCACTCTCTCCAATGGCAATAGTTCTAAGCAAAAAATTCCAGCAGATGGAGTCCACAGGATCAGAGTGGACTTTAAGGTGGCCAACATGAGT-
GCTAAGGACGGCAAGTGTACACT
TGAACATCCTCAGCACTCTCTCCAATGGCAATAGTTCTAAGCAAAAAATTCCAGCAGATGGAGTCCACAGGATCAGAGTGGACTTTAAGGTGGCCAACATGAGT-
GCTAAGGACGGCACGTGTACAC
TCTCCAATGGCAATAGTTCTAAGCAAAAAATTCCAGCAGATGGAGTCCACAGGATCAGAGTGGACTTTAAGGTGGCCAACATGAGTGCTAAGGACGGCACGTG-
TACACTGCAGGACTGCATGTACA
TGGACTTTAAGGTGGCCAACATGAGTGCTAAGGACGGCACGTGTACACTGCAGGACTGCATGTACAAGGATGTGCAGAAGGACTGGCCTGGCTACTCG-
GAGGGGGACCAGCAGCAGATCGGAAGAG
TGGACTTTAAGGTGGCCAACATGAGTGCTAAGGACGGCACGTGTACACTGCAGGACTGCATGTACAAGGATGTGCAGAAGGACTGGCCTGGCTACTCG-
GAGGGGGACCAGCAGCAGATCGGAAGAG
CTTTGAACATCCTCAGCACTCTCTCCAATGGCAATAGTTCTAAGCAAAAAATTCCAGCAGATGGAGTCCACAGGATCAGAGTGGACTTTAAGGTGGCCAACAT-
GAGTGCTAAGGACGGCACGTGTA
CAGGATCAGAGTGGACTTTAAGGTGGCCAACATGAGTGCTAAGGACGGCACGTGTACACTGCAGGACTGCATGTACAAGGATGTGCAGAAGGACTGGC-
CTGGCTACTCGGAGGGGGACCAGCAGCT
ATCAGAGTGGACTTTAAGGTGGCCAACATGAGTGCTAAGGACGGCACGTGTACACTGCAGGACTGCATGTACAAGGATGTGCAGAAGGACTGGCCTG-
GCTACTCGGAGGGGGACCAGCAGCTGCTG
GGAGTCCACAGGATCAGAGTGGACTTTAAGGTGGCCAACATGAGTGCTAAGGACGGCACGTGTACACTGCAGGACTGCATGTACAAGGATGTGCAGAA-
GGACTGGCCTGGCTACTCGGAGGGGGAC
GCACTCTCTCCAATGGCAATAGTTCTAAGCAAAAAATTCCAGCAGATGGAGTCCACAGGATCAGAGTGGACTTTAAGGTGGCCAACATGAGTGCTAAGGACG-
GCACGTGTACACTGCAGGACTGCA
GCAATAGTTCTAAGCAAAAAATTCCAGCAGATGGAGTCCACAGGATCAGAGTGGACTTTAAGGTGGCCAACATGAGTGCTAAGGACGGCACGTGTACACT-
GCAGGACTGCATGTACAAGGATGTGC
GTGGACTTTAAGGTGGCCAACATGAGTGCTAAGGACGGCACGTGTACACTGCAGGACTGCATGTACAAGGATGTGCAGAAGGACTGGCCTGGC-
TACTCGGAGGGGGACCAGCAGCTGCTGAAGCGG
ATGCAGGCACTTTGAACATCCTCAGCACTCTCTCCAATGGCAATAGTTCTAAGCAAAAAATTCCAGCAGATGGAGTCCACAGGATCAGAGTGGACTTTAAGGTGGC-
CAACATGAGTGCTAAGGACG
CACAGGATCAGAGTGGACTTTAAGGTGGCCAACATGAGTGCTAAGGACGGCACGTGTACACTGCAGGACTGCATGTACAAGGATGTGCAGAAGGACTG-
GCCTGGCTACTCGGAGGGGGACAGATCG
CTCCAATGGCAATAGTTCTAAGCAAAAAATTCCAGCAGATGGAGTCCACAGGATCAGAGTGGACTTTAAGGTGGCCAACATGAGTGCTAAGGACGGCACGTGTA-
CACTGCAGGACTGCATGTACAA
CTCCAATGGCAATAGTTCTAAGCAAAAAATTCCAGCAGATGGAGTCCACAGGATCAGAGTGGACTTTAAGGTGGCCAACATGAGTGCTAAGGACGGCACGTGTA-
CACTGCAGGACTGCATGTACAA
CAGGCACTTTGAACATCCTCAGCACTCTCTCCAATGGCAATAGTTCTAAGCAAAAAATTCCAGCAGATGGAGTCCACAGGATCAGAGTGGACTTTAAGGTGGC-
CAACATGAGTGCTAAGGACGGCA
CAGCACTCTCTCCAATGGCAATAGTTCTAAGCAAAAAATTCCAGCAGATGGAGTCCACAGGATCAGAGTGGACTTTAAGGTGGCCAACATGAGTGCTAAGGACG-
GCACGTGTACACTGCAGGACTG
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cytogenetics, FISH, and RNA-sequencing—that helped 
us identify the present MLL exon 9-ELL exon 6 fusion. 
G-banding analysis showed what appeared to be a regular 
chromosomal translocation t(11;19)(q23;p13) (Fig.  4a), 
a well-known change in acute leukemia. FISH showed 
that although MLL was split, the distal part of the gene 
was moved not to the derivative 19 but, surprisingly, to 
the long arm of chromosome 8 (Fig.  4b). Finally, RNA-
sequencing showed that exon 9 of MLL was fused to exon 
6 of ELL (Table 2). RT-PCR using a new reverse primer 
located in exon 8 of ELL (primer ELL-1044R1, MLL-
3878F and ELL-1044R1 primer combination) then con-
firmed the fusion transcript (Fig. 4d, e).
In 2009, De Braekeleer and coworkers reported a case 
of congenital acute monoblastic leukemia with a three-
way translocation, t(1;19;11)(p36;p13.11;q23), which 
involved the MLL gene and generated an MLL-ELL 
fusion identical to that of the present case [8, 16, 18]. To 
the best of our knowledge, these are the only two cases 
hitherto reported in which exon 6 of ELL is fused to MLL. 
It is certainly intriguing that three-way translocations, 
an unusual phenomenon behind MLL-rearrangements, 
had occurred in both cases; it may hint at some cur-
rently hidden mechanism behind the generation of the 
genomic change. The number of AML cases with MLL 
exon 9-ELL exon 6 fusions might actually be underesti-
mated when assessed by means of RT-PCR amplifications 
using primer sets based on hitherto published studies [3, 
10, 11, 15, 29, 30]. This situation may be remedied by use 
of a new RT-PCR method that includes primers to detect 
fusion of MLL also with exon 6 of ELL [18].
Current knowledge holds that there are three types of 
MLL-ELL fusion transcripts (Fig. 5). Type 1, found in the 
majority of cases, is characterized by ELL exon 2 being 
fused to 5´-MLL [3, 8–13]. Type 2 was so far found in only a 
single case of chronic myelomonocytic leukemia (CMML) 
that transformed to AML; it had exon 3 of ELL fused to 
5´-MLL [15]. Type 3, of which the present case is one of 
two, is caused by a three-way translocation leading to the 
fusion of exon 6 of ELL with MLL (present case; [8, 16, 18]). 
All three MLL-ELL fusion proteins contain the amino-
terminal region of MLL which includes the AT hooks, the 
methyltransferase domain, and the repression domain [31].
The case we describe presented unusual clinical fea-
tures. Most conspicuous were the widespread, very pain-
ful bone lesions with soft tissue involvement which were 
interpreted as multiple myeloid sarcomas and extensive 
bone infarcts, not mere marrow infiltration. The valid-
ity of this diagnosis is supported by the gradual, pro-
tracted resolution of these lesions taking place during 
and after therapy. To the best of our knowledge, only four 
cases, including the present one, have been reported of 
very young AML patients displaying myelomonocytic 
features, myeloid sarcomas, and involvement of the 
MLL-ELL fusion gene [8, 16, 32, 33]. The four patients 
have similar cytogenetic and genetic (MLL-ELL fusion) 
features. Three of them had a three-way translocation 
generating the MLL-ELL fusion: the present case with 
t(8;19;11)(q24;p13;q23), a female newborn with t(1;19;11)
(p36;p13.11;q23) [16, 32], and a three-month-old boy 
with t(6;19;11)(p22;p13;q23) [33]. None of the patients 
had the type 1 MLL-ELL fusion (see above). In the 
patient with t(1;19;11)(p36;p13.11;q23), the data suggest 
an MLL exon 9-ELL exon 6 fusion transcript, similar to 
our case [16, 32]. In a two-month-old child reported by 
De Braekeler et al, the genomic breakpoints in MLL and 
The sequences of ELL are in bold
Table 2 continued
ATCAGAGTGGACTTTAAGGTGGCCAACATGAGTGCTAAGGACGGCACGTGTACACTGCAGGACTGCATGTACAAGGATGTGCAGAAGGACTGGCCTG-
GCTACTCGGAGGGGGACCAGCAGCTGCTG
GTTCTAAGCAAAAAATTCCAGCAGATGGAGTCCACAGGATCAGAGTGGACTTTAAGGTGGCCAACATGAGTGCTAAGGACGGCACGTGTACACTGCAGGACT-
GCATGTACAGATCGGAAGAGCGTC
AATAGTTCTAAGCAAAAAATTCCAGCAGATGGAGTCCACAGGATCAGAGTGGACTTTAAGGTGGCCAACATGAGTGCTAAGGACGGCACGTGTACACTGCAG-
GACTGCATGTACAAGGATGTGCAG
GTTCTAAGCAAAAAATTCCAGCAGATGGAGTCCACAGGATCAGAGTGGACTTTAAGGTGGCCAACATGAGTGCTAAGGACGGCACGTGTACACTGCAGGACT-
GCATGTACAAGGATGTGCAGAAGG
AATAGTTCTAAGCAAAAAATTCCAGCAGATGGAGTCCACAGGATCAGAGTGGACTTTAAGGTGGCCAACATGAGTGCTAAGGACGGCACGTGTACACTGCAG-
GACTGCATGTACAAGGATGTGCAG
CACAGGATCAGAGTGGACTTTAAGGTGGCCAACATGAGTGCTAAGGACGGCACGTGTACACTGCAGGACTGCATGTACAAGGATGTGCAGAAGGACTG-
GCCTGGCTACTCGGAGGGGGACCAGCAG
CAGCACTCTCTCCAATGGCAATAGTTCTAAGCAAAAAATTCCAGCAGATGGAGTCCACAGGATCAGAGTGGACTTTAAGGTGGCCAACATGAGTGCTAAGGACG-
GCACGTGTACACTGCAGGACTG
ATGGAGTCCACAGGATCAGAGTGGACTTTAAGGTGGCCAACATGAGTGCTAAGGACGGCACGTGTACACTGCAGGACTGCATGTACAAGGATGTGCAGAA-
GGACTGGCCTGGCTACTCGGAGGGGG
CTCAGCACTCTCTCCAATGGCAATAGTTCTAAGCAAAAAATTCCAGCAGATGGAGTCCACAGGATCAGAGTGGACTTTAAGGTGGCCAACATGAGTGCTAA-
GGACGGCACGTGTACACTGCAGGAC
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Fig. 5 Properties of the ELL gene. a Ideogram of chromosome 19 showing the location of the ELL gene in chromosome subband 19p13.11 (vertical 
red line). b Exon intron structure of the ELL gene. Vertical boxes indicate exons. The breakpoints (BP) have been found in introns 1, 2, and 5. Vertical 
arrows indicate the genomic BP regions. The transcription is from centromere (cen) to telomere (tel). c Diagram showing mRNA of ELL with acces‑
sion number NM_006532.3. The exons which code for protein are in black. The vertical arrows indicate the fusion points 1, 2, and 3 in the MLL‑ELL 
fusion transcripts. d Diagram showing the ELL protein, the known domains, and the phosphorylation sites. FP1, FP2, and FP3 are the fusion points 
with the MLL in the three types (1, 2, and 3) of MLL‑ELL fusion protein. All three MLL‑ELL proteins retain the occludin homology domain, the SMC_
prok_A domain, the nuclear localization signal, and the three phosphorylation sites
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ELL indicated an MLL exon 9-ELL exon 3 fusion tran-
script [8, 32]. In the three-month-old boy with t(6;19;11)
(p22;p13;q23), the translocation resulted in an MLL exon 
8-ELL exon 3 fusion transcript [33].
Due to the small number of patients described, it is 
impossible to make definite statements about prognosis. 
Nevertheless, treatment results so far on patients carrying 
rare MLL-ELL fusion genes seem to have been encour-
aging. The newborn patient did not receive antileukemic 
therapy and died 24 h after birth [32], but the three treated 
patients, including the present case, went into remission 
[32, 33]. Two of them seem to be long-term survivors [32, 
33], and our patient is in complete clinical remission 1 year 
after diagnosis. The clinical importance of the small clone 
with a 7q deletion that has emerged in remission is unclear. 
Recurrent cytogenetic abnormalities are sometimes seen 
in AML and ALL patients who are in complete clinical 
remission and may persist for years in the bone marrow 
even in the absence of progression to leukemia [20–23]. A 
wait-and-see approach is therefore prudent.
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